HLN logo

Haleon plc Stock Price

LSE:HLN Community·UK£31.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 51 Fair Values set on narratives written by author

HLN Share Price Performance

UK£3.50
-0.28 (-7.42%)
15.4% undervalued intrinsic discount
UK£4.14
Fair Value
UK£3.50
-0.28 (-7.42%)
15.6% undervalued intrinsic discount
UK£4.15
Fair Value
Price UK£3.50
AnalystConsensusTarget UK£4.15
AnalystHighTarget UK£5.03
AnalystLowTarget UK£3.15

HLN Community Narratives

AnalystConsensusTarget·
Fair Value UK£4.14 15.4% undervalued intrinsic discount

Emerging Markets And Digital Channels Will Transform Global Reach

0users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
AnalystHighTarget·
Fair Value UK£5.03 30.3% undervalued intrinsic discount

Aging Global Demand And Digital Reach Will Drive Consumer Healthcare

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value UK£3.2 9.5% overvalued intrinsic discount

Rising Regulatory Costs And Shifting Consumer Preferences Will Undermine Performance

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
UK£4.14
15.4% undervalued intrinsic discount
Revenue growth
3.86% p.a.
Profit Margin
15.14%
Future PE
22.72x
Share price in 2028
UK£5.02
UK£5.03
30.3% undervalued intrinsic discount
Revenue growth
4.38% p.a.
Profit Margin
16.45%
Future PE
25.41x
Share price in 2028
UK£6.05
UK£3.2
9.5% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
2.4% p.a.
Profit Margin
14.49%
Future PE
19.44x
Share price in 2028
UK£3.85

Snowflake Analysis

Solid track record and fair value.

1 Risk
3 Rewards

Haleon plc Key Details

UK£11.0b

Revenue

UK£4.0b

Cost of Revenue

UK£7.0b

Gross Profit

UK£5.5b

Other Expenses

UK£1.5b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 25, 2026
0.17
63.56%
13.81%
52.6%
View Full Analysis

About HLN

Founded
1715
Employees
24561
CEO
Brian McNamara
WebsiteView website
www.haleon.com

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Recent HLN News & Updates

Recent updates

No updates